A series of 1-methyl-4,5-diphenylimidazoles 6 with various patterns of m-halogen substitution at the 5-phenyl ring were tested for cytotoxicity in cancer and nonmalignant cell lines and for their capacity to prevent tube formation in HUVEC cultures. Unlike the monofluoro and difluoro derivatives 6a and 6e, the monobromo and diiodo analogs 6c and 6h were strongly cytotoxic and inhibited the polymerization of tubulin and the tube formation by HUVEC. The dibromo derivative 6g displayed a unique selectivity for KB-3-1 cervix and PC-3 prostate cancer cells. It also inhibited the tube formation by HUVEC and the polymerization of tubulin which is indicative of its potential antiangiogenic activity in solid tumors.
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Combretastatin A-4 (CA-4, 1a, Fig. 1 ) was first isolated from the bark of the South African Cape Bushwillow (Combretum caffrum) and was later shown to have pronounced antivascular properties. 1 Prodrugs of 1a with improved bioavailability such as the phosphate fosbretabulin have been investigated in a number of clinical trials which proved their selective impact on tumor vasculature. 2 Other CA-4 analogs are also being studied, for example, the serine amide ombrabulin which is currently in phase III trials for the treatment of NSCLC. 3 Vascular disrupting agents (VDA) are an intriguing alternative for the therapy of highly vascularized tumors or such no longer responding to conventional chemotherapy. 4 The mechanism of action of VDA is typically associated with destabilization of microtubules, activation of Rho signaling and reorganization of the cellular actin cytoskeleton. Morphologically, endothelial cells exposed to VDA get rounded and blebby which eventually leads to the collapse of the tumor blood vessels and thus to tumor necrosis. 5 However, due to their insufficient cytotoxicity, 1a and its prodrugs have to be administered as part of combination regimens with other anticancer drugs such as carboplatin or bevacizumab to prevent tumor relapse. [6] [7] [8] In addition, they tend to isomerize to the biologically inactive trans-form. azole analogs of 1a are stable to cis-trans isomerization and are orally applicable in most cases. 17 Recently, we published their preparation by van Leusen reaction of p-toluenesulfonylmethyl isocyanide (TosMIC) with aryl aldehydes as an alternative to the palladium-mediated aryl coupling developed by Bellina et al. 18 We had also identified imidazoles 3 as examples of this type with (ii) POCl 3 , Et 3 N, DME, 3 h, À5°C, 31% (two steps); (iii) ArCHO, MeNH 2 (33% in EtOH), AcOH, EtOH, 2 h, reflux; then 5, K 2 CO 3 , DME/EtOH, 6 h, reflux; (iv) 3 M HCl/dioxane, CH 2 Cl 2 , 10 min, rt, 25-91% (two steps). exceptional in vivo activity and tolerance. 19 Now we sought to further optimize the drug profiles of similar imidazoles by attaching halogen substituents to the tetrasubstituted A-ring.
The new 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(halophenyl)imidazoles 6 feature A-and B-rings transposed with respect to 3 and were prepared from TosMIC 5. 3-Fluoro-4-methoxybenzaldehyde 4 was reacted with p-toluenesulfinic acid and formamide in the presence of camphorsulfonic acid (CSA) to give a tosylmethylformamide intermediate, which was dehydrated to 5 by POCl 3 . The halogenated benzaldehydes used for the van Leusen reaction with 5 were prepared according to known literature methods 12, 15, 20 and converted to their N-methylimines. Reaction of the latter with 5 and addition of HCl/dioxane finally afforded the imidazolium salts 6 (Scheme 1). Growth inhibition of cells of L929 mouse fibroblasts, human KB-3-1 cervix carcinoma, PC-3 prostate cancer, PtK2 potoroo kidney cells and primary human dermal fibroblasts (NHDF) by compounds 3 and 6 was assessed by MTT assays ( Table 1 ). The monobromo derivative 6c and the diiodo compound 6h proved most active. They were also distinctly more cytotoxic to cancer cells than the known trimethoxy derivative 3a and also than 3b, the best performer of our previously published imidazole series. 19 In contrast, the monofluoro (6a), difluoro (6e) and dichloro (6f) analogs were of moderate cytotoxicity. Compounds 6c and 6h were also most active with respect to suppressing tube formation in HUVEC cultures at minimal inhibitory concentrations of ca. 100 nM. The dibromide 6g was selectively efficacious against the cervix and prostate cancer cells for yet unknown reason. The anticancer active compounds 6c, 6g, and 6h were in almost all cases less harmful to the nontumor derived L929, PtK2, and NHDF cells than to the cancer cells. Figure 2 shows the inhibitory effects of selected test compounds on the tube formation propensity of HUVEC. While tube formation was observed even in the presence of ca. 4 lg/mL (=12 lM) of the tris-fluoro derivative 6e, the dibromo analog 6g was required at concentrations only slightly greater than 130 ng/mL (=270 nM) to prevent tube formation. The most effective compound, the diiodo derivative 6h, suppressed tube formation even at this low concentration (cf. Supplementary data file for other compounds).
The capacities of compounds 3a, 6a, 6c, 6e, 6g, and 6h to inhibit the polymerization of tubulin as assessed by a standard turbidimetric method employing freshly isolated porcine microtubule protein 21 correlated well with their inhibitory effects on HUVEC tube formation and their cytotoxicities. The highly cytotoxic and HUVEC tube inhibiting compounds 6c, 6g, and 6h were also strong inhibitors of tubulin polymerization (Fig. 3) . The least cytotoxic and least effective HUVEC tube suppressor 6e did not interfere with tubulin polymerization. Interestingly, the known trimethoxyphenyl compound 3a while strongly cytotoxic, had but a minute effect on tubulin polymerization. Except for 6e, a destruction of microtubules was observed for all test compounds when applied at 10 lg/mL to PtK2 potoroo (Potorous tridactylis) kidney epithelial cells which are easy to monitor due to their flat shape (Fig. 4) . The greatest damage was caused by compounds 6h and 6c (not shown since similar to that of 6h), which is in line with their high cytotoxicity in these cells.
In conclusion, we prepared eight new N-methylimidazolebridged analogs 6a-h of combretastatin A-4 (1a) featuring a 3-fluoro-4-methoxyphenyl B-ring and various m-halogenated A-rings. Some structure-activity relations already emerged in our tests for cytotoxicity and antiangiogenic activity. In both series of imidazoles 6 with mono-and dihalogenated A-rings the antiproliferative activity was lowest for the fluoro (6a and 6e) and the chloro (6b and 6f) derivatives. Substitution of one m-methoxy group of the A-ring by bromine or replacement of both m-methoxy groups by two iodine atoms led to strongly cytotoxic and antiangiogenic agents 6c and 6h. Their activities exceeded even that of the known trimethoxy derivative 3a. This confirms recent findings by Myers et al. 15 who discovered that bigger bromo (1c) or iodo (1d), but not small fluoro substituents at both meta-positions of ring A of stilbenoid analogs of 1a led to enhanced potency against HUVEC cells. The dibromophenyl substituted imidazole 6g was a potent suppressor of HUVEC tube formation, of tubulin polymerization, and of the growth of KB-3-1 cervix and PC-3 prostate cancer cells. For growth inhibition of the L929 mouse fibroblasts a residue larger than bromine, for example, iodine (6h) or methoxy (6c), has to be present in one of the meta-positions of the B-ring. It will be interesting to see whether the new imidazoles are as well tolerated in mice as the previously reported analogs 3.
